Novartis Announces the EU Approval of first-in-class Aimovig®️(erenumab) for Migraine Prevention

 Novartis Announces the EU Approval of first-in-class Aimovig®️(erenumab) for Migraine Prevention

Novartis Announces the EU Approval of first-in-class Aimovig®️(erenumab) for Migraine Prevention

Shots:
  •   Results of 2600 patients trial reported significant i.e. ≥50% reduction in migraine days with comparable safety and tolerability to PBO
  •   Aimovig works by blocking calcitonin gene-related peptide receptor (CGRP-R) which plays vital role in migraine
  •   Can be self-administered every four weeks with the Sure Click®️ auto injector pen, device commonly used for different conditions
  •  Aimovig is already approved by FDA in May 17, followed by Australia and Swissmedic on July 3 & 13 respectively in 2018 with more expected approvals globally

Click here to read full press release/ article | Ref: Novartis | Image: Forbes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post